Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients

AIMS: Cetuximab associated with cisplatin and 5‐fluorouracil is used to treat patients with inoperable or metastatic head and neck squamous cell carcinomas (HNSCC) up until disease progression or unacceptable toxicities. To date, no biomarkers of efficacy are available to select patients who will be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Le Louedec, Félicien, Alix‐Panabières, Catherine, Lafont, Thierry, Allal, Ben C., Garrel, Renaud, Digue, Laurence, Guigay, Joël, Cupissol, Didier, Delord, Jean‐Pierre, Lallemant, Benjamin, Alfonsi, Marc, Aubry, Karine, Mazel, Martine, Becher, François, Perriard, Françoise, Chatelut, Etienne, Thomas, Fabienne
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6533440/
https://ncbi.nlm.nih.gov/pubmed/30811063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13907
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados